Cite
CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study.
MLA
Munoz, J., et al. “CC‐99282 plus R‐CHOP in Patients (Pts) with Previously Untreated Aggressive B‐cell Lymphoma (A‐BCL): Early Safety and Efficacy Results from a Phase 1b Study.” Hematological Oncology, vol. 41, June 2023, pp. 584–86. EBSCOhost, https://doi.org/10.1002/hon.3164_438.
APA
Munoz, J., Hoffmann, M., Westin, J., Vassilakopoulos, T. P., García, S. A. M., Rueda, D. A., Jurczak, W., Kwiatek, M., Bouzani, M., Gkasiamis, A., Patel, A., Boucaud, F., Li, J., & Nowakowski, G. S. (2023). CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study. Hematological Oncology, 41, 584–586. https://doi.org/10.1002/hon.3164_438
Chicago
Munoz, J., M. Hoffmann, J. Westin, T. P. Vassilakopoulos, Sancho, A. M. García, Domínguez, A. Rueda, W. Jurczak, et al. 2023. “CC‐99282 plus R‐CHOP in Patients (Pts) with Previously Untreated Aggressive B‐cell Lymphoma (A‐BCL): Early Safety and Efficacy Results from a Phase 1b Study.” Hematological Oncology 41 (June): 584–86. doi:10.1002/hon.3164_438.